MEDEXUS PHARMACEUTICALS INC (MDP.CA) Fundamental Analysis & Valuation
TSX:MDP • CA58410Q2036
Current stock price
3.08 CAD
-0.07 (-2.22%)
Last:
This MDP.CA fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.
1. MDP.CA Profitability Analysis
1.1 Basic Checks
- MDP had negative earnings in the past year.
- In the past year MDP had a positive cash flow from operations.
- In multiple years MDP reported negative net income over the last 5 years.
- In multiple years MDP reported negative operating cash flow during the last 5 years.
1.2 Ratios
- With a decent Return On Assets value of -0.18%, MDP is doing good in the industry, outperforming 69.70% of the companies in the same industry.
- Looking at the Return On Equity, with a value of -0.52%, MDP is in the better half of the industry, outperforming 72.73% of the companies in the same industry.
- MDP's Return On Invested Capital of 3.02% is fine compared to the rest of the industry. MDP outperforms 69.70% of its industry peers.
- MDP had an Average Return On Invested Capital over the past 3 years of 9.89%. This is in line with the industry average of 8.22%.
- The 3 year average ROIC (9.89%) for MDP is well above the current ROIC(3.02%). The reason for the recent decline needs to be investigated.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -0.18% | ||
| ROE | -0.52% | ||
| ROIC | 3.02% |
ROA(3y)0.64%
ROA(5y)-3.83%
ROE(3y)3.01%
ROE(5y)-32.83%
ROIC(3y)9.89%
ROIC(5y)N/A
1.3 Margins
- MDP's Operating Margin of 3.91% is fine compared to the rest of the industry. MDP outperforms 72.73% of its industry peers.
- With an excellent Gross Margin value of 53.87%, MDP belongs to the best of the industry, outperforming 81.82% of the companies in the same industry.
- In the last couple of years the Gross Margin of MDP has remained more or less at the same level.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 3.91% | ||
| PM (TTM) | N/A | ||
| GM | 53.87% |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y1.84%
GM growth 5Y-1.43%
2. MDP.CA Health Analysis
2.1 Basic Checks
- With a Return on Invested Capital (ROIC) just above the Cost of Capital (WACC), MDP is creating some value.
- MDP has more shares outstanding than it did 1 year ago.
- Compared to 5 years ago, MDP has more shares outstanding
- The debt/assets ratio for MDP has been reduced compared to a year ago.
2.2 Solvency
- MDP has an Altman-Z score of 0.64. This is a bad value and indicates that MDP is not financially healthy and even has some risk of bankruptcy.
- MDP's Altman-Z score of 0.64 is fine compared to the rest of the industry. MDP outperforms 60.61% of its industry peers.
- MDP has a debt to FCF ratio of 1.48. This is a very positive value and a sign of high solvency as it would only need 1.48 years to pay back of all of its debts.
- Looking at the Debt to FCF ratio, with a value of 1.48, MDP belongs to the top of the industry, outperforming 90.91% of the companies in the same industry.
- MDP has a Debt/Equity ratio of 0.35. This is a healthy value indicating a solid balance between debt and equity.
- Looking at the Debt to Equity ratio, with a value of 0.35, MDP is in line with its industry, outperforming 51.52% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.35 | ||
| Debt/FCF | 1.48 | ||
| Altman-Z | 0.64 |
ROIC/WACC0.34
WACC8.89%
2.3 Liquidity
- A Current Ratio of 1.12 indicates that MDP should not have too much problems paying its short term obligations.
- Looking at the Current ratio, with a value of 1.12, MDP is doing worse than 78.79% of the companies in the same industry.
- A Quick Ratio of 0.62 indicates that MDP may have some problems paying its short term obligations.
- MDP has a Quick ratio of 0.62. This is in the lower half of the industry: MDP underperforms 78.79% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 1.12 | ||
| Quick Ratio | 0.62 |
3. MDP.CA Growth Analysis
3.1 Past
- MDP shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -112.14%.
- The Revenue has decreased by -9.23% in the past year.
- The Revenue has been growing slightly by 7.82% on average over the past years.
EPS 1Y (TTM)-112.14%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-90%
Revenue 1Y (TTM)-9.23%
Revenue growth 3Y12.2%
Revenue growth 5Y7.82%
Sales Q2Q%-15.56%
3.2 Future
- MDP is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 53.29% yearly.
- The Revenue is expected to grow by 10.80% on average over the next years. This is quite good.
EPS Next Y-112.62%
EPS Next 2Y101%
EPS Next 3Y109.18%
EPS Next 5Y53.29%
Revenue Next Year-8.18%
Revenue Next 2Y2.38%
Revenue Next 3Y8.11%
Revenue Next 5Y10.8%
3.3 Evolution
- The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
4. MDP.CA Valuation Analysis
4.1 Price/Earnings Ratio
- MDP reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
- MDP is valuated cheaply with a Price/Forward Earnings ratio of 6.87.
- MDP's Price/Forward Earnings ratio is rather cheap when compared to the industry. MDP is cheaper than 84.85% of the companies in the same industry.
- MDP's Price/Forward Earnings ratio indicates a rather cheap valuation when compared to the S&P500 average which is at 22.19.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | 6.87 |
4.2 Price Multiples
- 93.94% of the companies in the same industry are more expensive than MDP, based on the Enterprise Value to EBITDA ratio.
- MDP's Price/Free Cash Flow ratio is rather cheap when compared to the industry. MDP is cheaper than 90.91% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 4.18 | ||
| EV/EBITDA | 6.04 |
4.3 Compensation for Growth
- A more expensive valuation may be justified as MDP's earnings are expected to grow with 109.18% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y101%
EPS Next 3Y109.18%
5. MDP.CA Dividend Analysis
5.1 Amount
- No dividends for MDP!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
MDP.CA Fundamentals: All Metrics, Ratios and Statistics
TSX:MDP (3/27/2026, 7:00:00 PM)
3.08
-0.07 (-2.22%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)02-11 2026-02-11/amc
Earnings (Next)N/A N/A
Inst Owners0.65%
Inst Owner ChangeN/A
Ins Owners7.65%
Ins Owner ChangeN/A
Market Cap99.48M
Revenue(TTM)99.43M
Net Income(TTM)-272.00K
Analysts82.5
Price Target7.48 (142.86%)
Short Float %N/A
Short RatioN/A
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)54.21%
Min EPS beat(2)0.99%
Max EPS beat(2)107.43%
EPS beat(4)4
Avg EPS beat(4)77.72%
Min EPS beat(4)0.99%
Max EPS beat(4)144%
EPS beat(8)7
Avg EPS beat(8)78.39%
EPS beat(12)9
Avg EPS beat(12)100.87%
EPS beat(16)11
Avg EPS beat(16)73.38%
Revenue beat(2)0
Avg Revenue beat(2)-2.26%
Min Revenue beat(2)-4.22%
Max Revenue beat(2)-0.29%
Revenue beat(4)0
Avg Revenue beat(4)-1.39%
Min Revenue beat(4)-4.22%
Max Revenue beat(4)-0.29%
Revenue beat(8)2
Avg Revenue beat(8)-0.34%
Revenue beat(12)4
Avg Revenue beat(12)-1.11%
Revenue beat(16)7
Avg Revenue beat(16)0.69%
PT rev (1m)6.47%
PT rev (3m)18.69%
EPS NQ rev (1m)0%
EPS NQ rev (3m)50%
EPS NY rev (1m)85.71%
EPS NY rev (3m)81.82%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)0.82%
Revenue NY rev (1m)0.42%
Revenue NY rev (3m)-0.11%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | 6.87 | ||
| P/S | 0.72 | ||
| P/FCF | 4.18 | ||
| P/OCF | 4.13 | ||
| P/B | 1.37 | ||
| P/tB | N/A | ||
| EV/EBITDA | 6.04 |
EPS(TTM)-0.02
EYN/A
EPS(NY)0.45
Fwd EY14.55%
FCF(TTM)0.74
FCFY23.92%
OCF(TTM)0.75
OCFY24.21%
SpS4.27
BVpS2.24
TBVpS-0.98
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -0.18% | ||
| ROE | -0.52% | ||
| ROCE | 4.2% | ||
| ROIC | 3.02% | ||
| ROICexc | 3.61% | ||
| ROICexgc | 107.26% | ||
| OM | 3.91% | ||
| PM (TTM) | N/A | ||
| GM | 53.87% | ||
| FCFM | 17.26% |
ROA(3y)0.64%
ROA(5y)-3.83%
ROE(3y)3.01%
ROE(5y)-32.83%
ROIC(3y)9.89%
ROIC(5y)N/A
ROICexc(3y)12.45%
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)13.73%
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y1.84%
GM growth 5Y-1.43%
F-Score5
Asset Turnover0.64
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.35 | ||
| Debt/FCF | 1.48 | ||
| Debt/EBITDA | 1.33 | ||
| Cap/Depr | 2.1% | ||
| Cap/Sales | 0.21% | ||
| Interest Coverage | 1.57 | ||
| Cash Conversion | 127.65% | ||
| Profit Quality | N/A | ||
| Current Ratio | 1.12 | ||
| Quick Ratio | 0.62 | ||
| Altman-Z | 0.64 |
F-Score5
WACC8.89%
ROIC/WACC0.34
Cap/Depr(3y)16.17%
Cap/Depr(5y)70.8%
Cap/Sales(3y)1.03%
Cap/Sales(5y)5.33%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-112.14%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-90%
EPS Next Y-112.62%
EPS Next 2Y101%
EPS Next 3Y109.18%
EPS Next 5Y53.29%
Revenue 1Y (TTM)-9.23%
Revenue growth 3Y12.2%
Revenue growth 5Y7.82%
Sales Q2Q%-15.56%
Revenue Next Year-8.18%
Revenue Next 2Y2.38%
Revenue Next 3Y8.11%
Revenue Next 5Y10.8%
EBIT growth 1Y-74.14%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year73.75%
EBIT Next 3Y62.94%
EBIT Next 5Y44.59%
FCF growth 1Y-17.31%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-17.2%
OCF growth 3YN/A
OCF growth 5YN/A
MEDEXUS PHARMACEUTICALS INC / MDP.CA Fundamental Analysis FAQ
What is the ChartMill fundamental rating of MEDEXUS PHARMACEUTICALS INC (MDP.CA) stock?
ChartMill assigns a fundamental rating of 4 / 10 to MDP.CA.
What is the valuation status of MEDEXUS PHARMACEUTICALS INC (MDP.CA) stock?
ChartMill assigns a valuation rating of 6 / 10 to MEDEXUS PHARMACEUTICALS INC (MDP.CA). This can be considered as Fairly Valued.
Can you provide the profitability details for MEDEXUS PHARMACEUTICALS INC?
MEDEXUS PHARMACEUTICALS INC (MDP.CA) has a profitability rating of 5 / 10.
What is the financial health of MEDEXUS PHARMACEUTICALS INC (MDP.CA) stock?
The financial health rating of MEDEXUS PHARMACEUTICALS INC (MDP.CA) is 4 / 10.